Detail akcie Pharvaris Rg online

Business Summary: Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Pharvaris NV revenues was not reported. Net loss increased 30% to EUR129M. Higher net loss reflects Research & Development Expense - Bal increase of 31% to EUR63.5M (expense), Finance income (expenses) increase from EUR2.4M to EUR10.6M (expense), Personnel expenses increase of 41% to EUR26.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -EUR1.84 to -EUR2.28.